A randomized, double-blind, two-treatment, single-period, single-dose, parallel design, comparative bioavailability study between RTPR- 021 (test adalimumab) 40 mg/0.8 ml prefilled syringe from Reliance Life Sciences Pvt. Ltd., India and Humira® (reference adalimumab) 40 mg/0.8 ml prefilled syringe from Abbott biotechnology Germany in healthy, adult, human subjects following subcutaneous administration under fasting condition.

Trial Profile

A randomized, double-blind, two-treatment, single-period, single-dose, parallel design, comparative bioavailability study between RTPR- 021 (test adalimumab) 40 mg/0.8 ml prefilled syringe from Reliance Life Sciences Pvt. Ltd., India and Humira® (reference adalimumab) 40 mg/0.8 ml prefilled syringe from Abbott biotechnology Germany in healthy, adult, human subjects following subcutaneous administration under fasting condition.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top